Amnova Clinical Research | Irvine, CA

Research site

Location

4902 Irvine Center Drive, Suite 104, Irvine, California, United States of America

Site insights

Top conditions

Top treatments

BPN14770

JZP258-407

Cannabidiol

Ecopipam Hydrochloride

MRM-3379

ZYN002

Selnoflast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Maggie Wang

Verified by this site

Active trials

5 of 10 total trials

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events (RIVULET)

The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for...

Enrolling

Atherosclerosis

Drug: Selnoflast

Drug: Placebo

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-...

Active, not recruiting

Fragile X Syndrome

Drug: Zatolmilast/ BPN14770

Detection of Sleep Stages and Arousals Using Neural Network Classifiers (SSAM)

The objective of this clinical study is to evaluate the accuracy of the Smart Mask V1 System (herein 'Smart Mask') in measuring sleep stages-Stage N1...

Not yet enrolling

Sleep Disordered Breathing (SDB)

Sleep Apnea

Device: EnsoSleep

Diagnostic Test: Polysomnography

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery)....

Active, not recruiting

Fragile X Syndrome

Drug: ZYN002 - Cannabidiol Transdermal Gel

Locations recently updated

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male...

Enrolling

Fragile X Syndrome

Drug: Low dose of MRM-3379 Open-Label

Drug: Middle Dose of MRM-3379